Proceso de desensibilización ANTI-HLA en receptores de donante vivo HLA Clase II incompatible con anticuerpos donante específico
[ANTI-HLA desensitization process in HLA II incompatible living donor recipients with specific donor antibodies]Karen Courville1
, Norman Emilio Bustamante1, Maydeline Pecchio2, Luis Ortiz3, Alejandro Vernaza-Kwiers31. Hospital Dr. Gustavo Nelson Collado; 2. Hospital Dr. Gustavo N. Collado; 3. Complejo Hospitalario Metropolitano Dr. Arnulfo Arias Madrid.
Descargas
Resumen
Introducción: El trasplante renal es la opción terapéutica que ofrece la mejor expectativa de vida en los pacientes con enfermedad renal crónica. Muchos pacientes sensibilizados permanecen largo tiempo en lista de espera, aumentando su morbi-mortalidad en diálisis.
Objetivos: evaluar el uso de terapia de desensibilización en pacientes con anticuerpos anti HLA Clase II contra su donante vivo relacionado, identificar factores de riesgo temprano de requerimiento de biopsia renal por sospecha de rechazo y evaluar los costos relacionados.
Resultados: Realizamos valoración de terapia de desensibilización a 3 pacientes, con una disminución en los valores de anticuerpos donante específico a menos de 1000 de MFI, con un índice de RIS bajo, por lo que se procedió con el trasplante, sin complicaciones inmediatas y con un seguimiento a 18 meses sin deterioro de función renal.
Conclusiones: La desensibilización previa a trasplante renal permite disminuir el título de anticuerpos donantes específicos preformados y llevar a cabo el trasplante renal, con una buena evolución del paciente y del injerto superior a permanecer en diálisis.
Abstract
Introduction: Renal transplantation is the therapeutic option that offers the best life expectancy in patients with chronic kidney disease. Many sensitized patients remain on the waiting list for a long time, increasing their morbidity-mortality on dialysis.
Objectives: to evaluate the use of desensitization therapy in patients with Class II HLA antibodies against their related living donor, identify early risk factors for renal biopsy requirement for suspected rejection, and assess related costs.
Results: We perform desensitization therapy assessment to 3 patients, with a decrease in specific donor antibody values to less than 1000 MFI, with a low RIS index, so transplantation was carried out, without immediate complications and with a follow-up to 18 months without impaired renal function.
Conclusions: Pre-renal transplant desensitization reduces the titles of preformed specific donor antibodies and performs renal transplantation, with a good evolution of the patient and the graft, superior than remaining on dialysis.
Citas
[1] Wolfe RA, Ashby VB, Milford EL et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. New Eng J Med. 1999: 341(23), 1725-1730.
[2] Valentin MO, Ruiz JC, Vega R, Martín C, Matesanz R; working group PATHI. Implementation of a National Priority Allocation System for Hypersensitized Patients in Spain Based on Virtual Crossmatch: Initial Results. Transplant Proc. 2016 Nov; 48(9):2871-2875.
[3] Vernaza A. Estadísticas Trimestrales. Laboratorio Nacional de Trasplante, Caja de Seguro Social. Panamá. 2019. www.css.gob.pa.
[4] Marfo K, Lu A, Ling M, Akalin E. Desensitization protocols and their outcome. Clin J Am Soc Nephrol 2011; 6(4): 922-936.
[5] Keith DS, Vranic GM. Approach to the highly sensitized kidney transplant candidate. Clin J Am Soc Nephrol. 2016; 11(4): 684-693.
[6] Hart A, Smith JM, Skeans MA et al. OPTN/SRTR 2016 annual data report: Kidney. Am J Transplant. 2018; 18: 18-113.
[7] Patel R, Terasaki PI. Significance of the positive crossmatch test in kidney transplantation. N Engl J Med. 1969; 280(14): 735-739.
[8] Garovoy MR, Rheinschmidt MA, Bigos M, Perkins H, Colombe B, Feduska N. Flow cytometry analysis: a high technology cross-match technique facilitating transplantation. Transplant Proc. 1983; 15: 1939–1945.
[9] Gebel HM, Bray RA. HLA antibody detection with solid phase assays: great expectations or expectations too great? Am J Transplant. 2014; 14(9): 1964-1975.
[10] Malvezzi P, Jouve T, Noble J, Rostaing L. Desensitization in the Setting of HLA-Incompatible Kidney Transplant. Exp Clin Transplant. 2018 Aug; 16(4):367-375.
[11] Sanoff SL, Balogun RA, Lobo PL. The role of therapeutic apheresis in high immunologic risk renal transplantation: a review of current trends. Semin Dial. 2012; 25(2):193-200.
[12] Stegall MD, Gloor J, Winters JL, Moore SB, Degoey S. A comparison of plasmapheresis versus high dose IVIG desensitization in renal allograft recipients with high levels of donor specific alloantibody. Am J Transplant. 2006; 6(2), 346-351.
[13] Vo AA, Lukovsky M, Toyoda M et al. Rituximab and intravenous immune globulin for desensitization during renal transplantation. N Eng J Med. 2008; 359(3), 242-251.
[14] Okada D, Okumi M, Kakuta Y et al. Outcome of the risk stratified desensitization protocol in donor specific antibody positive living kidney transplant recipients: a retrospective study. Transpl Int. 2018; 31(9): 1008-1017.
[15] Qiagen. Manual Del kit QIAamp® DSP DNA FFPE Tissue. Alemania, 2017. p 1-28. www.qiagen.com
[16] Bodmer WF. The HLA system: introduction. Br Med Bull. 1978 Sep; 34(3):213-6.
[17] Klein J, Sato A. The HLA system. First of two parts. N Engl J Med. 2000 Sep 7; 343(10):702-9.
[18] Gibney EM, Cagle LR, Freed B. Detection of donor-specific antibodies using HLA-coated microspheres: another tool for kidney transplant risk stratification. Nephrol Dial Transplant. 2006 Sep; 21(9):2625-9.
[19] Eng HS, Bennett G, Tsiopelas E et al. Anti-HLA donor-specific antibodies detected in positive B-cell crossmatches by Luminex predicts late graft loss. Am J Transplant. 2008 Nov;8(11):2335-42.
[20] Aubert V, Venetz JP, Pantaleo G, Pascual M. Low levels of human leukocyte antigen donor-specific antibodies detected by solid phase assay before transplantation are frequently clinically irrelevant. Hum Immunol. 2009 Aug; 70(8):580-3.
[21] McKenna RM, Takemoto SK, Terasaki PI. Anti-HLA antibodies after solid organ transplantation. Transplantation. 2000 Feb 15;69(3):319-26.
[22] Molina J, Navas A, Agüera ML, Rodríguez-Benot A. Avances en inmunología del trasplante renal. NefroPlus 2018;10(2):11-19.
[23] Keith DS, Vranic GM. Approach to the highly sensitized kidney transplant candidate. Clin J Am Soc Nephrol; 206 11(4): 684-693.
[24] Ministerio de La Presidencia. Gaceta Oficial Digiatl. Ley 3 de 8 de febrero de 2010 General de Trasplantes de Componentes Anatómicos. Asamblea Nacional de Panamá. Gaceta Oficial: 26468-b. https://www.gacetaoficial.gob.pa/pdfTemp/26468_B/GacetaNo_26468b_20100210.pdf.
[25] Orandi BJ, Luo X, Massie AB al. Survival benefit with kidney transplants from HLA-incompatible live donors. N Engl J Med. 2016; 374(10): 940-950.
[26] Montgomery R A, Lonze BE, King KE et al. Desensitization in HLA-incompatible kidney recipients and survival. N Engl J Med. 2011; 365(4): 318-326.
[27] Yang CY, Lee CY, Yeh CC, Tsai MK. Renal transplantation across the donor-specific antibody barrier: Graft outcome and cancer risk after desensitization therapy. J Formos Med Assoc 2016; 115(6): 426-433.
[28] De Sousa-Amorim E, Revuelta I, Blasco M et al. Desensitization before living donor kidney transplantation in highly HLA-sensitized patients: a single-center study. Transplant Proc. 2015 Oct;47(8):2332-5.
[29] Bentall A, Cornell LD, Gloor JM et al. Five year outcomes in living donor kidney transplants with a positive crossmatch. Am J Transplant 2013 Jan; 13(1):76-85.
[30] Abu Jawdeh BG, Cuffy MC, Alloway RR, Shields AR, Woodle ES. Desensitization in kidney transplantation: review and future perspectives. Clin Transplant 2014 Apr;28(4):494-507.
[31] Riella LV, Safa K, Yagan J et al. Long-term outcomes of kidney transplantation across a positive complement-dependent cytotoxicity crossmatch. Transplantation 2014 Jun 27; 97(12):1247-52.
[32] Lim WH, Wong G, Heidt S, Claas FHJ. Novela spects of epitope matching and practical application in kidney transplantation. Kidney Int. 2018; 93:314-24.
[33] Lefaucheur C, Loupy A, Hill GS. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol. 2010 Aug; 21(8):1398-406.
[34] Jordan SC, Vo AA. Desensitization offers hope to highly HLA-sensitized patients for a longer life expectancy after incompatible kidney transplant. Am. J. Kidney Dis, 59(6), 758-760.
[35] Fernandez C, Calvo M, Leite N et al. Kidney transplantation from HLA-incompatible live donors: efficiency and outcome of 32 patients after desensitisation. Nefrologia. 2017; 37:638-45.
[36] Mehra NK, Baranwal AK. Clinical and immunological relevance of antibodies in solid organ transplantation. Int J Immunogenet. 2016;43:351-68.
[37] Vo AA, Petrozzino J, Yeung K et al. Efficacy, outcomes, and cost-effectiveness of desensitization using IVIG and rituximab. Transplantation. 2013; 95(6): 852-858.
[38] Moreno-Velásquez I, Tribaldos-Causadias M, Valdés R et al. End-stage renal disease-financial costs and years of life lost in Panama: a cost-analysis study. BMJ Open. 2019 May 27; 9(5):e027229.
[39] Jordan S, Cunningham-Rundles C, McEwan R. Utility of intravenous immune globulin in kidney transplantation: efficacy, safety, and cost implications. Am J Transplant. 2003 Jun; [
Licencia
Derechos de autor 2021 Infomedic Intl.Derechos autoriales y de reproducibilidad. La Revista Médica de Panama es un ente académico, sin fines de lucro, que forma parte de la Academia Panameña de Medicina y Cirugía. Sus publicaciones son de tipo acceso gratuito de su contenido para uso individual y académico, sin restricción. Los derechos autoriales de cada artículo son retenidos por sus autores. Al Publicar en la Revista, el autor otorga Licencia permanente, exclusiva, e irrevocable a la Sociedad para la edición del manuscrito, y otorga a la empresa editorial, Infomedic International Licencia de uso de distribución, indexación y comercial exclusiva, permanente e irrevocable de su contenido y para la generación de productos y servicios derivados del mismo. En caso que el autor obtenga la licencia CC BY, el artículo y sus derivados son de libre acceso y distribución.
